• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

SPG302

Background

SPG302 is a small molecule compound developed by Spinogenix, a biotechnology company based in Los Angeles, California. SPG302 is believed to act on a regulator of the cytoskeleton, with the goal of increasing dendritic spine density and, in turn, improving cognitive and motor function (Trujillo-Estrada et al., 2021). SPG302 is currently in clinical trials for ALS/MND, Alzheimer’s disease (AD) and schizophrenia.

Some preclinical work has investigated the effects of SPG302 in models of Alzheimer’s disease and spinal cord injury. In a transgenic mouse model of Alzheimer’s disease, SPG302 was seen to mildly restore synaptic density in the hippocampus and improve cognitive function in hippocampal based tasks. Increased expression of postsynaptic proteins and synaptic density was observed (Trujillo-Estrada et al., 2021). In rats subjected to spinal cord injury, SPG302 marginally sped the recovery of diaphragm muscle activity (Fogarty et al., 2023).

Trial Design & Results

A first in human, phase 1/2a randomised, double-blind and placebo controlled study was started in July 2023 across 4 sites in Australia (Clinicaltrials.gov ID: NCT05882695). The study was composed of 3 parts:

  • Part 1 – a single ascending dose (SAD) study in healthy volunteers, who were randomised 3:1 SPG302 to placebo
  • Part 2 – a multiple ascending dose (MAD) study in healthy volunteers who were randomised 3:1 SPG302 to placebo and received a daily dose over 5 days, with a follow up safety visit on day 12 (±3 days)
  • Part 3 – people living with ALS/MND were randomised 3:1 SPG302 to placebo. They were given a daily dose for 28 days, with a safety visit conducted 30 days (±7 days) after the final dose.

The primary outcome measure of all parts of the study was to assess incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs). Secondary outcomes in healthy volunteers included SP302 plasma concentrations and the effect of food on the pharmacokinetics of the compound. Secondary outcomes for participants with ALS also included clinical measures such as spirometry and the Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R). Participants living with ALS/MND from the phase I study were given the opportunity to take part in an open label extension to investigate the long-term safety, tolerability, and efficacy of SPG302 administered orally (Clinicaltrials.gov ID: NCT06903286). A total of 16 people living with ALS/MND will continue with the dose they received at the end of the first trial and will self-administer SPG302 orally for up to 52 weeks; they will have an in-person clinic visit every 3 months (± 3 days) and a monthly phone call.

Some of the results from the top line results from the Phase 2 program were presented at the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Annual Meeting in October 2025. The company communicated through a press release that SPG302 is safe and well tolerated in the studied cohort over 6 months at an oral dose of 300 mg daily, with some suggested clinical benefits. However, no data is publicly available yet to corroborate this statement. Some additional data was presented at the MNDA Symposium on December 5th, 2025, suggesting mild effect in slow progressors according to exploratory measures. The trial was relatively small, so these findings should be interpreted with caution and will need to be confirmed in larger studies.

SPG302 was granted orphan drug designation for the treatment of ALS/MND in both the US and European Union. In May 2025, the Food and Drug Administration (FDA, US) gave authorization for an Expanded Access Cost Recovery Program (EACRP) for 200 people living with ALS/MND who meet eligibility criteria in the US (Clinicaltrials.gov ID: NCT07088159). An EACRP allows sponsors to recover the direct costs of providing access to a therapy, without making a profit. As a result, people living with the disease are likely required to pay for access to the program.

SPG302 is also being studied in two phase II clinical trials for Alzheimer’s disease (in Australia; Clinicaltrials.gov ID: NCT06427668) and schizophrenia (in the US and Australia; Clinicaltrials.gov ID: NCT06442462).

Summary

SPG302 is a synthetic small molecule compound produced by Spinogenix, which targets defective synapses. A randomised, double blind, placebo-controlled study was carried out to assess safety and tolerability of SPG302 in healthy volunteers and people living with ALS/MND. No results are publicly available for this study yet.  Participants with ALS/MND have been given the opportunity to take part in an open label extension for up to 52 weeks to evaluate long term safety and tolerability of SPG302.

International Alliance of ALS/MND Associations
April 2026


Disclaimer: Consult with a healthcare professional to determine if you could potentially participate in a SPG302 clinical trial. Always disclose your medical history, including any drugs, natural supplements, or herbal medicines currently being used.

The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • NurOwn
  • Clene Nanomedicine – CNM-Au8
  • ILB
  • Kadimastem – AstroRx
  • Neuronata-R / Lenzumestrocel
  • NeuroSense – PrimeC
  • NP001
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials
  • SPG302
  • Regulatory T Cell Enhancing Therapies
  • Ulefnersen

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Murat Morali, Turkey

    Murat Morali, Turkey

  • Mark Miller, UK

    Mark Miller, UK

  • JP

    JP

  • Wiebke Braach, Germany

    Wiebke Braach, Germany

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • David Solomon, UK

    David Solomon, UK

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Anthony Lynch, Australia

    Anthony Lynch, Australia

  • Daniel Hare, USA

    Daniel Hare, USA

  • Glen Elison, USA

    Glen Elison, USA

  • Ali Var, Turkey

    Ali Var, Turkey

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Verónica Isabel Castro Molina, Argentina

    Verónica Isabel Castro Molina, Argentina

  • Jorge Luis Fernández Romero, Mexico

    Jorge Luis Fernández Romero, Mexico

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Fabio Correia, Brazil

    Fabio Correia, Brazil

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Alfredo Santos, Colombia

    Alfredo Santos, Colombia

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Cassio Fernando da Silva, Brazil

    Cassio Fernando da Silva, Brazil

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • Ann Nicol, USA

    Ann Nicol, USA

  • Alejandro Aquino, Argentina

    Alejandro Aquino, Argentina

  • Len Johnrose, England

    Len Johnrose, England

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Liam Dwyer, England

    Liam Dwyer, England

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Vincent Bourque, Canada

    Vincent Bourque, Canada
    vincent_bourque

  • Magdalena Ayala Rodríguez, Mexico

    Magdalena Ayala Rodríguez, Mexico

  • Ana Lilia Rodriguez, Mexico

    Ana Lilia Rodriguez, Mexico

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Sam Hayden-Harler, UK

    Sam Hayden-Harler, UK

  • Olga, Argentina

    Olga, Argentina

  • Cliff Marshman, USA

    Cliff Marshman, USA
    CliffMarshman

  • Mauril Bélanger, Canada

    Mauril Bélanger, Canada

  • Purningam Jacob, India

    Purningam Jacob, India

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Christian Bär, Germany

    Christian Bär, Germany

  • Jean

    Jean
    jean

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login